Open an Account
search icon
3
NOTIFICATIONS
Best Algo trading app in India
Bigul

Intimation Of Meeting Of Board Of Directors Scheduled To Be Held On May 27, 2017 And Closure Of Trading Windows.

 In compliance with the provisions of Regulation 29 of the SEBI (Listing Obligations and Disclosures Requirements) Regulation 2015, we hereby inform that the meeting of the Board of Directors of the Company will be held on Saturday, the May 27, 2017 to consider, inter alia, to approve the Audited Financial Results for the year ended on March 31, 2017. We further inform that as per Code of Conduct for prevention of Insider Trading adopted by the...
29-04-2017
Bigul

Zydus Cadila gets USFDA nod for anti-hypertensive tablets

 Healthcare player Zydus Cadila informed about receiving the final approval from the US drug regulator US Food and Drug Administration (USFDA) to market Olmesartan Medoxomil tablets in the US market.
26-04-2017
Bigul

Updates

 We enclose herewith a copy of press release dated April 26, 2017, titled Zydus receives final approval from the USFDA for Cholestyramine for Oral Suspension USP.
26-04-2017
Bigul

Zydus Cadila gets final USFDA nod for Olmesartan Medoxomil tablets

 Healthcare player Zydus Cadila on Tuesday informed about receiving the final approval from the US Food and Drug Administration (USFDA) to market Olmesartan Medoxomil tablets in the US market. The...
25-04-2017
Bigul

Updates

 Zydus receives final approval from the USFDA for Olmesartan Medoxomil Tablets. The contents of the press release give full details. Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.
25-04-2017
Bigul

Certificate Under Regulation 40 (9) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Half Year Ended On March 31, 2017.

 In compliance with the provisions of Regulation 40 (9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are forwarding herewith the Certificate of Mr. Manoj Hurkat, Practicing Company Secretary for the Half Year ended on March 31, 2017 received on April 13, 2017
13-04-2017
Bigul

Updates

 As required under regulation 33(3)(c)(ii) of SEBI [Listing Obligations and Disclosure Requirements] Regulations, 2015, we hereby inform that the Company will publish audited financial results for the F.Y. 2016-17 within 60 days of the end of financial year i.e. by May 30, 2017.
10-04-2017
Bigul

Statement Of Investor Complaints As On March 31, 2017.

 In compliance with the provisions of Regulation 13 (3) of the SEBI (Listing Obligations and Disclosures Requirements) Regulation 2015, the status of Investor Complaints as on March 31, 2017 is as under: Sr. No.ParticularsStatus of Complaints 1.Complaints pending at the beginning of the QuarterNIL 2.Complaints received during the Quarter6 3.Complaints disposed of during the Quarter6 4.Complaints remaining unresolved at the end of the QuarterNIL
10-04-2017
Bigul

Shareholding for the Period Ended March 31, 2017

 Cadila Healthcare Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2017. For more details, kindly Click here
10-04-2017
Bigul

Cadila Healthcare says Changodar plant has got no USFDA observation

 The plant was inspected by the US FDA between April 3 and April 7
08-04-2017
Next Page
Close

Let's Open Free Demat Account